Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6252W HIGH $9.65
Volume
182.31 K
Value Traded
115.35 K
Short % Float
11.95%
-4.24%Week
-29.81%1 Month
+31.61%3 Month
-17.52%6 Month
-99.83%5 Year
-99.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.52 M
EPS (TTM)
-2.61
P/E Ratio
-
Ent. Value
4.01 M
Total Shares
6.66 M
Float Shares
5.54 M
Insiders
16.72%
Institutions
12.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
FBLG Catalyst Timeline
Dated clinical, regulatory and corporate events for FibroBiologics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for FibroBiologics, Inc.
197Total events
11Upcoming
12Tier-1 (high impact)
2024 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Composition Patent FiledIP / Competition
FibroBiologics files U.S. patent application for cell-based in-body peptide production technology (GLP-1, GIP, GLP-2)
▲Patent GrantedIP / Competition
European Patent Office grants European Patent No. 3568465 'Methods of Enhancing Fibroblast Therapeutic Activity'
disc degeneration; angiogenesis; cell and tissue regenerationsource ↗
▼Equity OfferingCorporate
Closing of $0.5 million private placement with Chief Scientific Officer
▲Patent GrantedIP / Competition
USPTO issued U.S. Patent No. 12,721,866 covering therapeutic use of fibroblasts in wound healing
wound healingsource ↗
●Manufacturing MilestoneCYWC628CMC / Inspection
Third batch of CYWC628 drug product released and shipped to Australia
diabetic foot ulcerssource ↗
▲Patent GrantedIP / Competition
IP Australia accepts patent application for Cannabidiol Adjuvant Therapy for Degenerative Disc Disease
degenerative disc diseasesource ↗
▲Preclinical PoCFSdCSPreclinical
Preclinical study shows cartilage repair within four weeks of single FSdCS injection
degenerative joint diseasesource ↗
▲Patent GrantedIP / Competition
USPTO issued U.S. Patent No. 12,691,147 covering methods for treatment of Type 1 Diabetes using fibroblasts in facilitation of islet engraftment
Type 1 Diabetessource ↗
▲Patent GrantedIP / Competition
European Patent No. EP 3043825 B1 granted for gene therapy for cartilage regeneration
cartilage repairsource ↗
▲First Patient DosedCYWC628Trial
First patients dosed in Phase 1/2 trial of CYWC628 in diabetic foot ulcers
diabetic foot ulcerssource ↗
▲Patent GrantedIP / Competition
Notice of allowance for patent covering wound healing methods
▼Equity OfferingCorporate
Completed $9.0 million private placement and $3.0 million public offering
●Manufacturing MilestoneCYWC628CMC / Inspection
Completed manufacturing of three cGMP batches of CYWC628
▲Manufacturing MilestoneCYWC628CMC / Inspection
Completed manufacturing of third batch of CYWC628 drug product
diabetic foot ulcerssource ↗
◆Trial CompletionCYWC628Trial
Complete Phase 1/2 clinical trial in Australia in DFU patients
diabetic foot ulcerssource ↗
▼Equity OfferingCorporate
Completed $9.0 million private placement and $3.0 million public offering
●Manufacturing MilestoneCYWC628CMC / Inspection
Completed manufacturing of three cGMP batches of CYWC628
diabetic foot ulcerssource ↗
▲Patent GrantedIP / Competition
Notice of allowance for patent covering methods of treating wounds with 3D spheroid fibroblasts
wound healingsource ↗
●Poster PresentationPresentation
Poster presentations at Keystone Symposia and SID 2026 Annual Meeting
▲Preclinical PoCPreclinical
Preclinical results for HDF spheroids in burn wound healing
burn woundssource ↗
▼Equity OfferingCorporate
Closed private placement raising $3.0 million upfront with potential additional $6.0 million from warrant exercise
◆Oral PresentationPresentation
Chairman & CEO Pete O'Heeron to present at A4LI's H-SPAN Summit at Georgetown University
▼Equity OfferingCorporate
Private placement of common stock and warrants for up to $9.0 million
▲Patent GrantedIP / Competition
USPTO issued Notice of Allowance for patent covering topical fibroblast spheroid therapy for wound healing
wound healingsource ↗
●Manufacturing MilestoneCYWC628CMC / Inspection
Completed manufacturing of first two batches of third GMP manufacturing run
diabetic foot ulcerssource ↗
●Manufacturing MilestoneCYWC628CMC / Inspection
Drug product from second GMP manufacturing run released and scheduled to ship to Australia
diabetic foot ulcerssource ↗
▲First Patient DosedCYWC628Trial
First patients enrolled and dosed in Phase 1/2 trial of CYWC628 for diabetic foot ulcers
diabetic foot ulcerssource ↗
▲First Patient DosedCYWC628Trial
First patients dosed in Phase 1/2 trial of CYWC628 for diabetic foot ulcers
diabetic foot ulcerssource ↗
●Composition Patent FiledIP / Competition
Filed provisional patent application for oral administration of fibroblast therapeutics
chronic gastrointestinal disorderssource ↗
◆Poster PresentationCYPS317Presentation
Poster presentation of preclinical data for CYPS317 at SID 2026
psoriasissource ↗
▲Poster PresentationCYPS317Presentation
Preclinical data for CYPS317 presented at SID 2026 Annual Meeting
psoriasissource ↗
●Preclinical PoCPreclinical
Strategic expansion of fibroblast platform to target Hantavirus
Hantavirus pulmonary syndrome (HPS)source ↗
▲Preclinical PoCPreclinical
Preclinical data show HDF spheroids reprogram burn wound environment, reduce inflammation and scarring markers
burn woundssource ↗
▲Manufacturing MilestoneCYWC628CMC / Inspection
First cGMP batch of CYWC628 released for clinical use
diabetic foot ulcerssource ↗
●Poster PresentationCYPS317Presentation
Poster presentation on CYPS317 preclinical data at SID 2026
psoriasissource ↗
▼Equity OfferingCorporate
Raised approximately $2.5 million net in a registered direct offering
◆Poster PresentationPresentation
Preclinical data for thymic organoid platform presented at Keystone Symposia on Aging and Immunity
age-related immune declinesource ↗
▲First Patient DosedCYWC628Trial
Dose first patient in phase 1/2 trial for CYWC628
diabetic foot ulcerssource ↗
Past FDA Catalysts and PDUFA Decisions
How FBLG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$1M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 81%
Micro Cap(rank 535 of 660)
Percentile Rank
FibroBiologics, Inc. faces pipeline headwinds (25/100), with $390M risk-adjusted pipeline value, led by Tolerogenic Fibroblasts in Multiple Sclerosis, Relapsing-Remitting (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tolerogenic Fibroblasts Monoclonal antibodyCompletedNCT05080270 | Multiple Sclerosis, Relapsing-Remitting | Phase 1 | COMPLETED | 5 | Jun 8, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every FBLG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| fibroblasts | demyelinating diseases, including multiple sclerosis | 2025-04-02 | statistically significant increase in myelin expression within seven weeks after both single and multiple dose fibroblast treatmentsRead More | FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue RepairRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| O'HEERON PETEDirector, Officer (CHIEF EXECUTIVE OFFICER) | Grant/Award | 92,410 92,410 held | $0.00 | 05/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FBLG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in FBLG for Q2 2026. | ||||
FBLG Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FBLG ranks across every disease it competes in
Competitive Position is a premium feature
See how FBLG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFBLG News
-FBLG
Oct 7, 2026▲ +0.9%today
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
FibroBiologics has filed a U.S. patent application for a novel technology that enables the continuous production of therapeutic peptides, such as GLP-1, inside the body. This method aims to replace the need for regular injections or pills, potentially improving patient compliance. The technology could be applied to various diseases, including gastrointestinal and autoimmune conditions.
Read more →-FBLG
Sep 29, 2026FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
FibroBiologics has been granted a European Patent for methods to enhance fibroblast therapeutic activity. The patent focuses on using platelet rich plasma and cytokines to improve the regenerative properties of fibroblasts, particularly for spinal disc regeneration. This advancement could significantly impact treatments for chronic lower back pain, a prevalent medical issue.
Read more →-FBLG
Sep 17, 2026FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
FibroBiologics has successfully closed a $0.5 million private placement with its Chief Scientific Officer, Dr. Hamid Khoja. The investment involved the purchase of shares and warrants priced at market value. The funds will be allocated for general corporate purposes and working capital, supporting the company's expanding pipeline in chronic disease therapies.
Read more →-FBLG
Sep 3, 2026▼ -9.7%on this news
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
FibroBiologics has announced the issuance of a new U.S. patent covering the therapeutic use of fibroblasts for wound healing. The patent, which focuses on the topical administration of 3D spheroid fibroblasts, aims to accelerate the healing of chronic wounds, including diabetic ulcers. Preclinical studies indicate that this method significantly enhances healing rates, positioning FibroBiologics as a leader in fibroblast-based therapies.
Read more →-FBLG
Sep 1, 2026▲ +22.7%on this newsshared move
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
FibroBiologics has announced the issuance of a new U.S. patent for treating degenerative disc disease using fibroblast conditioned media. The patent covers methods that promote disc regeneration by utilizing fibroblast cells stimulated with opioid receptor antagonists and TLR agonists. This innovative approach aims to provide treatment options that repair the disc rather than just manage symptoms.
Read more →-FBLG
Aug 27, 2026▲ +5.7%on this news· ran to +50% by day 3shared move
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
FibroBiologics announced the release of the third batch of its CYWC628 drug product for a Phase 1/2 clinical trial targeting diabetic foot ulcers. The batch, manufactured in compliance with cGMP, is on its way to Australia for use in the study. The company anticipates reporting significant interim data later in 2026.
Read more →-FBLG
Aug 26, 2026FibroBiologics Regains Compliance with Nasdaq Trading Rules
FibroBiologics, Inc. has announced that it has regained compliance with Nasdaq's bid price requirement. This confirmation was received on August 25, 2026, allowing the company to continue trading on the Nasdaq Capital Market under the ticker FBLG. The company is now fully compliant with all Nasdaq listing standards.
Read more →-FBLG
Aug 24, 2026▼ -6.2%on this newsshared move
FibroBiologics Appoints Leigh Steinberg to Board of Directors
FibroBiologics has appointed Leigh Steinberg to its Board of Directors. Steinberg, a renowned sports agent and advocate for human longevity, brings extensive experience in chronic disease awareness and management. His involvement is expected to strengthen the company's efforts in developing fibroblast-based therapies. The CEO praised Steinberg's negotiating skills and influence across various sectors.
Read more →-FBLG
Aug 20, 2026▲ +8.4%on this news· ran to +21% by day 1shared move
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
FibroBiologics has announced the acceptance of an Australian patent for a novel therapy combining cannabidiol with fibroblast-based cell treatment for degenerative disc disease. This therapy aims to improve regeneration of intervertebral discs, which are commonly affected by chronic pain. The acceptance strengthens the company's intellectual property in a critical area of their clinical portfolio.
Read more →-FBLG
Aug 18, 2026▲ +11.8%on this news· ran to +41% by day 3shared move
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
FibroBiologics has announced promising results from a preclinical study using chondrocyte spheroids to repair cartilage in degenerative joints. The study showed significant cartilage repair within four weeks following a single injection. This innovative approach may offer a less invasive alternative to joint replacement, with a rapid manufacturing process that could reduce costs and improve accessibility for patients.
Read more →-FBLG
Aug 11, 2026▲ +5.1%on this news
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
FibroBiologics has been granted a U.S. patent for using fibroblasts to enhance the survival and function of transplanted insulin-producing islets. This innovation addresses significant challenges in islet transplantation, particularly the poor engraftment rates. The technology may increase donor tissue efficiency and has potential applications in various cell and tissue transplantation procedures.
Read more →-FBLG
Aug 5, 2026▲ +5.6%on this news· ran to +24% by day 1
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
FibroBiologics has been granted a European patent for a gene therapy aimed at regenerating cartilage by converting fibroblasts into cartilage-producing cells. This patent, which includes 12 claims, supports the company's strategy in orthopedics and degenerative disc pathways. The technology aims to address the limitations of current cartilage repair methods, offering a novel approach to tissue regeneration.
Read more →-FBLG
Jul 31, 2026▲ +12.9%on this news· ran to +46% by day 3shared move
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
FibroBiologics reported its second quarter 2026 financial results, highlighting the initiation of patient dosing in a phase 1/2 clinical trial for CYWC628 targeting diabetic foot ulcers. The company has strengthened its financial position through a $9.0 million private placement and a $3.0 million public offering. Positive preclinical results were noted, but the company also reported a net loss of approximately $4.1 million for the quarter.
Read more →-FBLG
Jul 9, 2026▲ +5.4%on this news
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
FibroBiologics has appointed Dr. Kathleen "Kate" Rubins to its Board of Directors. Dr. Rubins, a retired NASA astronaut and microbiologist, has been part of the company's Scientific Advisory Board since 2022. Her expertise in immune response and cell therapy is expected to guide the company's development of fibroblast-based treatments for chronic diseases.
Read more →-FBLG
Jul 7, 2026FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
FibroBiologics has successfully completed the manufacturing of the third batch of its CYWC628 drug product for a Phase 1/2 clinical trial focused on diabetic foot ulcers. The batch meets cGMP standards and is undergoing safety and quality testing. The company anticipates having enough product to complete the trial, potentially leading to cost savings and surplus doses for future research.
Read more →-FBLG
Jun 30, 2026▲ +19.2%on this news
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
FibroBiologics, a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. CEO Pete O'Heeron and CSO Hamid Khoja will engage in a fireside chat on June 30, 2026. The company aims to showcase its advancements in fibroblast-based therapeutics and will be available for one-on-one meetings during the event.
Read more →-FBLG
Jun 29, 2026▲ +19.2%on this newsshared move
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics has successfully closed a private placement raising $3 million, with the potential for an additional $6 million through warrant exercises. The company plans to use the proceeds for working capital and general corporate purposes. The offering was conducted under Nasdaq rules, and the securities are not registered under the Securities Act.
Read more →-FBLG
Jun 26, 2026▲ +12.7%on this news· ran to +24% by day 3shared move
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics, Inc. has announced a private placement of common stock and warrants, aiming to raise up to $9 million. The initial $3 million will be supplemented by potential proceeds of $6 million from warrant exercises. The offering is set to close around June 29, 2026, pending customary conditions. The funds will support working capital and corporate purposes.
Read more →-FBLG
Jun 22, 2026FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
FibroBiologics has announced that the USPTO issued a Notice of Allowance for its patent application on the therapeutic use of fibroblasts in wound healing. The patent includes 19 claims related to the topical administration of 3D spheroid fibroblasts for treating chronic wounds, particularly in patients with diabetes. This aligns with the company's lead program, CYWC628, currently in Phase 1/2 trials for diabetic foot ulcers.
Read more →-FBLG
Jun 16, 2026▼ -9.3%on this newsshared move
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
FibroBiologics has initiated patient dosing in its Phase 1/2 clinical trial for CYWC628, aimed at treating diabetic foot ulcers. The first doses were administered in early June 2026, with ongoing manufacturing efforts to support the trial. The investigational therapy is designed to enhance wound healing by utilizing fibroblast cells. The company emphasizes the importance of its consistent manufacturing capabilities for clinical success.
Read more →About FibroBiologics, Inc.
Headquarters9350 KIRBY DRIVE, HOUSTON, TX, 77054
BIOPHARMAWATCH ELITE PLUS
Trade the next FBLG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime